Trial Profile
24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Flibanserin (Primary)
- Indications Decreased libido; Female sexual dysfunction
- Focus Therapeutic Use
- Acronyms SNOWDROP
- Sponsors Sprout Pharmaceuticals
- 25 Sep 2021 Results of post-hoc analysis onset of flibanserin's treatment effect in naturally postmenopausal women with HSDD across the 6 subdomains of the FSFI, presented at the North American Menopause Society 2021 Annual Meeting.
- 16 May 2017 Results of a post-hoc analysis from three 24-week trials presented at the 112th Annual Meeting of the American Urological Association
- 02 Mar 2012 Company added in the association field as reported by ClinicalTrials.gov.